{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:10:30Z","timestamp":1787220630669,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.phrs.2014.05.002","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T16:32:08Z","timestamp":1400085128000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-8337","authenticated-orcid":false,"given":"Edgars","family":"Liepinsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Makrecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Kuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Cirule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Makarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduards","family":"Sevostjanovs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveiga","family":"Grinberga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinis","family":"Vilskersts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daina","family":"Lola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einars","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilmars","family":"Stonans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvalds","family":"Pugovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Dambrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2014.05.002_bib0005","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1194\/jlr.M800535-JLR200","article-title":"Novel role of FATP1 in mitochondrial fatty acid oxidation in skeletal muscle cells","volume":"50","author":"Sebastian","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2014.05.002_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/srep00079","article-title":"Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis","volume":"1","author":"Shriver","year":"2011","journal-title":"Sci Rep"},{"key":"10.1016\/j.phrs.2014.05.002_bib0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11897-013-0133-0","article-title":"Cardiac lipotoxicity: molecular pathways and therapeutic implications","volume":"10","author":"Drosatos","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.phrs.2014.05.002_bib0020","doi-asserted-by":"crossref","first-page":"H259","DOI":"10.1152\/ajpheart.01028.2002","article-title":"Effects of fatty acids in isolated mitochondria: implications for ischemic injury and cardioprotection","volume":"285","author":"Korge","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.phrs.2014.05.002_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1074248411419502","article-title":"The cardioprotective effect of mildronate is diminished after co-treatment with l-carnitine","volume":"17","author":"Kuka","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.05.002_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejphar.2011.02.019","article-title":"Anti-diabetic effects of mildronate alone or in combination with metformin in obese Zucker rats","volume":"658","author":"Liepinsh","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2014.05.002_bib0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00210-013-0849-0","article-title":"Activated peroxisomal fatty acid metabolism improves cardiac recovery in ischemia\u2013reperfusion","volume":"386","author":"Liepinsh","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.phrs.2014.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.03.005","article-title":"Modulation of the JAK\/ERK\/STAT signaling in melanocortin-induced inhibition of local and systemic responses to myocardial ischemia\/reperfusion","volume":"72","author":"Ottani","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.05.002_bib0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phrs.2010.06.002","article-title":"Hydrogen sulfide and ischemia\u2013reperfusion injury","volume":"62","author":"Nicholson","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.05.002_bib0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cvr\/cvn317","article-title":"Potential novel pharmacological therapies for myocardial remodelling","volume":"81","author":"Landmesser","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.phrs.2014.05.002_bib0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.111.243162","article-title":"Regulation of the inflammatory response in cardiac repair","volume":"110","author":"Frangogiannis","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.phrs.2014.05.002_bib0060","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.2042-7158.2011.01325.x","article-title":"Mildronate treatment alters gamma-butyrobetaine and l-carnitine concentrations in healthy volunteers","volume":"63","author":"Liepinsh","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.phrs.2014.05.002_bib0065","series-title":"Role of the adipocyte in development of type 2 diabetes","first-page":"107","article-title":"The regulation of energy metabolism pathways through l-carnitine homeostasis","author":"Liepinsh","year":"2011"},{"key":"10.1016\/j.phrs.2014.05.002_bib0070","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1039\/c4sc00020j","article-title":"Modulating carnitine levels by targeting its biosynthesis \u2013 selective inhibition of [gamma]-butyrobetaine hydroxylase","volume":"5","author":"Rydzik","year":"2014","journal-title":"Chem Sci"},{"key":"10.1016\/j.phrs.2014.05.002_bib0075","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1021\/jm401603e","article-title":"Targeting carnitine biosynthesis: discovery of new inhibitors against gamma-butyrobetaine hydroxylase","volume":"57","author":"Tars","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2014.05.002_bib0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/iub.323","article-title":"Enzymology of the carnitine biosynthesis pathway","volume":"62","author":"Strijbis","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.phrs.2014.05.002_bib0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/pr.54.4.589","article-title":"Pivalate-generating prodrugs and carnitine homeostasis in man","volume":"54","author":"Brass","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.phrs.2014.05.002_bib0090","doi-asserted-by":"crossref","first-page":"27078","DOI":"10.1074\/jbc.M110.109678","article-title":"Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis","volume":"285","author":"D\u2019Argenio","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.05.002_bib0095","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1017\/S000711450775691X","article-title":"Dietary oxidised fat up regulates the expression of organic cation transporters in liver and small intestine and alters carnitine concentrations in liver, muscle and plasma of rats","volume":"98","author":"Koch","year":"2007","journal-title":"Br J Nutr"},{"key":"10.1016\/j.phrs.2014.05.002_bib0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0005-2736(01)00328-5","article-title":"Na(+)-coupled transport of l-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney","volume":"1512","author":"Tamai","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2014.05.002_bib0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0925-4439(97)00089-6","article-title":"Secondary abnormality of carnitine biosynthesis results from carnitine reabsorptional system defect in juvenile visceral steatosis mice","volume":"1362","author":"Horiuchi","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2014.05.002_bib0110","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1046\/j.1432-1327.2001.02065.x","article-title":"Development and characterization of an animal model of carnitine deficiency","volume":"268","author":"Spaniol","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.phrs.2014.05.002_bib0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/0264-6021:3610417","article-title":"Carnitine biosynthesis in mammals","volume":"361","author":"Vaz","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2014.05.002_bib0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1050-1738(02)00175-5","article-title":"Mildronate: cardioprotective action through carnitine-lowering effect","volume":"12","author":"Dambrova","year":"2002","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.phrs.2014.05.002_bib0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.physbeh.2008.06.012","article-title":"Effect of inhibiting carnitine biosynthesis on male rat sexual performance","volume":"95","author":"Dambrova","year":"2008","journal-title":"Physiol Behav"},{"key":"10.1016\/j.phrs.2014.05.002_bib0130","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vascn.2012.11.001","article-title":"Troubleshooting digital macro photography for image acquisition and the analysis of biological samples","volume":"67","author":"Liepinsh","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.phrs.2014.05.002_bib0135","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/1087057113493006","article-title":"OCTN cation transporters in health and disease: role as drug targets and assay development","volume":"18","author":"Pochini","year":"2013","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.phrs.2014.05.002_bib0140","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.fjc.0000250077.07702.23","article-title":"Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction","volume":"48","author":"Liepinsh","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.phrs.2014.05.002_bib0145","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.lfs.2008.08.008","article-title":"Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart","volume":"83","author":"Liepinsh","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.phrs.2014.05.002_bib0150","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1476-5381.2009.00319.x","article-title":"Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats","volume":"157","author":"Liepinsh","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2014.05.002_bib0155","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1124\/dmd.108.023929","article-title":"The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate","volume":"37","author":"Grigat","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.phrs.2014.05.002_bib0160","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1002\/jps.22557","article-title":"Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2","volume":"100","author":"Diao","year":"2011","journal-title":"J Pharm Sci"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T17:31:38Z","timestamp":1716744698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814000619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":32,"alternative-id":["S1043661814000619"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.05.002","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}